Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (271-280 of 358) with videos related to

Pageof 36
Sort By:
Antiviral Therapy|May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN TrialVicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.
Current HIV Research|June 1, 2017
High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative DisordersAndrea Calcagno, Anna Lucchini, Daniele Caracciolo, et al.
Therapie|December 1, 2020
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective studySilvia Corcione, Amedeo De Nicolò, Tommaso Lupia, et al.
Journal of Neurovirology|December 16, 2017
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremiaMattia Trunfio, Sarah Beth Joseph, Valeria Ghisetti, et al.
The New Microbiologica|December 20, 2022
Preferences of PLWH and of clinicians for HIV treatment aimed at long-term successMassimo Andreoni, Andrea Antinori, Antonella Castagna, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2018
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugsJessica Cusato, Lucio Boglione, Amedeo De Nicolò, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale ScreeningAmedeo De Nicolò, Valeria Avataneo, Jessica Cusato, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 20, 2016
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical settingLetizia Marinaro, Andrea Calcagno, Diego Ripamonti, et al.
Antiviral Therapy|March 27, 2009
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyMatthijs van Luin, Wendy P Bannister, Amanda Mocroft, et al.
Therapeutic Drug Monitoring|March 13, 2012
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical settingMarco Siccardi, Antonio DʼAvolio, Sonia Rodriguez-Novoa, et al.
Pageof 36

Showing results (271-280 of 358) with videos related to

Sort By:
Pageof 36
Antiviral Therapy|May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN TrialVicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.
Current HIV Research|June 1, 2017
High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative DisordersAndrea Calcagno, Anna Lucchini, Daniele Caracciolo, et al.
Therapie|December 1, 2020
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective studySilvia Corcione, Amedeo De Nicolò, Tommaso Lupia, et al.
Journal of Neurovirology|December 16, 2017
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremiaMattia Trunfio, Sarah Beth Joseph, Valeria Ghisetti, et al.
The New Microbiologica|December 20, 2022
Preferences of PLWH and of clinicians for HIV treatment aimed at long-term successMassimo Andreoni, Andrea Antinori, Antonella Castagna, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2018
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugsJessica Cusato, Lucio Boglione, Amedeo De Nicolò, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale ScreeningAmedeo De Nicolò, Valeria Avataneo, Jessica Cusato, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 20, 2016
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical settingLetizia Marinaro, Andrea Calcagno, Diego Ripamonti, et al.
Antiviral Therapy|March 27, 2009
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyMatthijs van Luin, Wendy P Bannister, Amanda Mocroft, et al.
Therapeutic Drug Monitoring|March 13, 2012
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical settingMarco Siccardi, Antonio DʼAvolio, Sonia Rodriguez-Novoa, et al.
Pageof 36